Skip to main content
SpringerLink
Log in

Inflammatory bowel disease coexistent with viral hepatitis and HIV

  • Chapter
IBD 2007 — Achievements in Research and Clinical Practice

Part of the book series: Falk Symposium ((FASS,volume 159))

Abstract

Inflammatory bowel disease (IBD) may coexist with viral infections or may be complicated by the appearance of viral infections at a later stage. A further potentially dangerous event is the effect of agents used for treatment of IBD. Viral hepatitis is one of the most common viral infections worldwide. Although many viruses may cause either acute or chronic hepatocellular damage, hepatitic B virus (HBV) and hepatitic C virus (HCV) are the main viral liver infections. On the other hand, human immunodeficiency virus (HIV) might be a potential serious complication of IBD or it might also be influenced by the use of immunosuppressives or biological treatments of IBD. A review of the current Status of the influence of HBV, HCV and HIV infections on the management of IBD will be presented in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Biancon L, Pavia M, Del Vecchio Blanco G et al. and the GISC. Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis. 2001;7:287–94.

    Article  Google Scholar 

  2. Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology. 1992;16:13–18.

    Article  PubMed  CAS  Google Scholar 

  3. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009–22.

    Article  PubMed  CAS  Google Scholar 

  4. Sheen IS, Liaw YF, Lin SM, Chu CM. Severe clinical rebound upon withdrawal of corticosteroids before interferon therapy: incidence and risk factors. J Gastroenterol Hepatol. 1996;11:143–7.

    Article  PubMed  CAS  Google Scholar 

  5. Buti M, Esteban R, Esteban JI, Gonzales A, Guardia J. Severe hepatic failure after ARA-A prednisolone for chronic type B hepatitis. Gastroenterology. 1987;92:274–75.

    PubMed  CAS  Google Scholar 

  6. Laskus T, Slusarczyk J, Cianciara J, Loch T. Exacerbation of chronic active hepatitis B after short term corticosteroid therapy resulting in fatal liver failure. Am J Gastroenterol. 1990;85:1414–17.

    PubMed  CAS  Google Scholar 

  7. Biancone L, DelVecchio Blanco G, Pallone F, Castiglione F, Bresci G, Sturniolo G, Immunomodulatory drugs in Crohn’s disease patients with hepatitis B or C virus infection. Gastroenterology. 2002;122:593–4.

    Article  PubMed  Google Scholar 

  8. Khalidi M, Perillo RP. Interferon therapy of hepatitis B. Clin Liver Dis. 1999;3:363–87.

    Article  Google Scholar 

  9. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002;100:391–6.

    Article  PubMed  CAS  Google Scholar 

  10. Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol. 2000;18:368–78.

    Google Scholar 

  11. Flowers MA, Healthcote J, Wanless IR et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med. 1990;112:381–2.

    PubMed  CAS  Google Scholar 

  12. Ito S, Nakazono K, Murasawa A et al. Development of fulminant hepatitis B (precore variant mutant-type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44:339–42.

    Article  PubMed  CAS  Google Scholar 

  13. Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low-dose methotrexate therapy. J Rheumatol. 1998;25:2037–8.

    PubMed  CAS  Google Scholar 

  14. Kasahara S, Ando K, Saito K et al. Lack of tumour necrosis factor alpha induces impaired proliferation of hepatitis B virus specific T lymphocytes. J Virol. 2003;77:2469–76.

    Article  PubMed  CAS  Google Scholar 

  15. Feduchi F, Alonso MA, Carasco L. Human gamma interferon and tumour necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol. 1989;63:1354–9.

    PubMed  CAS  Google Scholar 

  16. Lucin P, Jonjic S, Messerle M, Polic B, Hengel H, Koszinowski UH. Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon gamma and tumour nerosis factor. J Gen Virol. 1994;75:101–10.

    Article  PubMed  CAS  Google Scholar 

  17. Schlaak JF, Tully G, Lohr HF, Gerken G, Meyer zum Buschenfelde KH. HBV-specific immune defect in chronic hepatitis B is correlated with a dysregulation of pro-and anti-inflammatory cytokines. Clin Exp Immunol. 1999;115:508–14.

    Article  PubMed  CAS  Google Scholar 

  18. Wong GH, Goedel DV. Tumour necrosis factor alpha and beta inhibit virus replication and synergize with interferons. Nature. 1986;323:819–22.

    Article  PubMed  CAS  Google Scholar 

  19. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996;4:25–36.

    Article  PubMed  CAS  Google Scholar 

  20. Oniankitan O, Duvoux C, Challine D et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004;31:107–9.

    PubMed  CAS  Google Scholar 

  21. del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Inglesias-Flores EM, deDios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm Bowel Dis. 2004;10:701–2.

    Article  PubMed  Google Scholar 

  22. Anelli MG, Torres DD, Manno C et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum. 2005;52:2519–20.

    Article  PubMed  Google Scholar 

  23. Reijasse D, Le Pendeven C, Cosnes J et al. Epstein-Barr virus viral load in Crohn’s disease: effect of immunosuppressive therapy. Inflamm Bowel Dis. 2004;10:85–90.

    Article  PubMed  Google Scholar 

  24. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut. 2004;53:1363–5.

    Article  PubMed  CAS  Google Scholar 

  25. Ueno Y, Shimamoto M, Miyanaka Y et al. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sei. 2005;50:163–6.

    Article  Google Scholar 

  26. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686–7.

    Article  PubMed  CAS  Google Scholar 

  27. Milloning G, Kerm M, Ludwiczek D, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV screening? World J Gastroenterol. 2006;12:974–6.

    Google Scholar 

  28. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF alpha therapy in rheumatoid arthritis and spondylarthropathies with coneurrent B or C chronic hepatitis. Rheumatology. 2006;45:1294–7.

    Article  PubMed  CAS  Google Scholar 

  29. Michel M, Duvoux C, Hezode C, Chergui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol. 2003;30:1624–5.

    PubMed  Google Scholar 

  30. Desai SB, Fürst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757–90.

    Article  PubMed  CAS  Google Scholar 

  31. Longo F, Hebuterne X, Tran A et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol. 2000;24:77–81.

    PubMed  CAS  Google Scholar 

  32. Bargiggia S, Thorburn D, Anderloni A et al. Is interferon-alpha safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther. 2005;22:209–15.

    Article  PubMed  CAS  Google Scholar 

  33. Magrin S, Craxi A, Fabiano C et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology. 1994;19:273–9.

    PubMed  CAS  Google Scholar 

  34. Barcena R, Oton E, Barreales M, Castillo M, Blesca C. Scarce influence of corticosteroid boluses on long-term viral load and liver histology in transplanted patients with recurrent hepatitis C. Transplant Proc. 2006;38:2502–4.

    Article  PubMed  CAS  Google Scholar 

  35. Stangl JR, Carrol KL, Illichmann M, Striker R. Effect of antimetabolite immunosuppresants on Flaviviridae, including hepatitis C virus. Transplantation. 2004;77:562–7.

    Article  PubMed  CAS  Google Scholar 

  36. Melon S, Galarraga MC, Villar M et al. Hepatitis C virus reactivation in anti-hepatitis C virus-positive renal transplant reeipients. Transplant Proc. 2005;37:2083–5.

    Article  PubMed  CAS  Google Scholar 

  37. Firpi RJ, Zhu H, Morelli G et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of sustained virological response after viral liver transplantation. Liver Transplant. 2006;12:51–7.

    Article  Google Scholar 

  38. Loho R, Turlin B, de Lajarte-Thirouard AS et al. Improved liver funetion and decreased hepatitis C viral load after tacrolimus was replaced by cyclosporine. Transplant Proc. 2005;37:2871–2.

    Article  CAS  Google Scholar 

  39. Oton E, Barcena R, Castillo M et al. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology. Transplant Proc. 2006;38:2499–501.

    Article  PubMed  CAS  Google Scholar 

  40. Chuang E, del Vecchio A, Smolinski S, Song XY, Sarisky R. Biomedicines to reduce inflammation but not viral load in chronic HCV — what’s the sense? Trends Biotechnol. 2004;22:517–23.

    Article  PubMed  CAS  Google Scholar 

  41. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078–82.

    Article  PubMed  CAS  Google Scholar 

  42. Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 2001;13:191–2.

    Article  PubMed  CAS  Google Scholar 

  43. Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn’s disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol. 2003;98:504–5.

    Article  PubMed  Google Scholar 

  44. Parke FA, Reveille JD. Anti-tumour necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum. 2004;51:800–4.

    Article  PubMed  CAS  Google Scholar 

  45. Magliocco MA, Gottlieb AB. Etarnecept therapy for patients with psoriatic arthritis and concurrent hepatitis C infection: report of 3 cases. J Am Acad Dermatol. 2004;51:580–4.

    Article  PubMed  Google Scholar 

  46. Zein NN. Etarnecept as an adjuvant to interferon and ribavirin in treatment naceve patients with chronic hepatitis C virus infection: a phase 2 randomized double blind placebo controlled study. J Hepatol. 2005;42:315–21.

    Article  PubMed  CAS  Google Scholar 

  47. James SP. Remission of Crohn’s disease after human immunodeficiency virus infection. Gastroenterology. 1988;95:667–9.

    Google Scholar 

  48. Yoshida EM, Chan NH, Herrick RA et al. Human immunodeficiency virus infection, the acquired immunodeficiency syndrome and inflammatory bowel disease. J Clin Gastroenterol. 1996;23:24–8.

    Article  PubMed  CAS  Google Scholar 

  49. Pospai D, Rene E, Fiasse R et al. Crohn’s disease stable remission after human immunodeficiency virus infection. Dig Dis Sei. 1998;43:412–19.

    Article  CAS  Google Scholar 

  50. Christ AD, Sieber CC, Cathomas G, Gyr K. Concomitant active Crohn’s disease and the acquired immunodeficiency syndrome. Scand J Gastroenterol. 1996;31:733–5.

    Article  PubMed  CAS  Google Scholar 

  51. Lantenbach E, Lichtenstein GR. Human immunodeficiency virus infection and Crohn’s disease: the role of CD4 cell in inflammatory bowel disease. J Clin Gastroenterol. 1997;25:456–9.

    Article  Google Scholar 

  52. Orenstein JM, Dieterich DT. The histopathology of 103 consecutive colonoscopy biopsies from 82 symptomatic patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med. 2001;125:1042–6.

    PubMed  CAS  Google Scholar 

  53. Kotler DD, Reka S, Orenstein JM et al. Chronic idiopathic esophageal ulceration in the acquired immunodeficiency syndrome. J Clin Gastroenterol. 1992;15:284–5.

    Article  PubMed  CAS  Google Scholar 

  54. Wilcox CM, Schwartz DA. Idiopathic anorectal ulceration in patients with human immunodeficiency virus infections. Am J Gastroenterol. 1994;89:599–604.

    PubMed  CAS  Google Scholar 

  55. Bach M, Howell DA, Valenti AJ et al. Aphthous ulceration of the gastrointestinal tract in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1990;112:465–7.

    PubMed  CAS  Google Scholar 

  56. Weber JN, Carmichael DJ, Boylston A et al. Kaposi’s sarcoma presenting as ulcerative colitis and complicated by toxic megacolon. Gut. 1985;26:295–300.

    Article  PubMed  CAS  Google Scholar 

  57. Roskeil DE, Hyde GM, Campbell AP et al. HIV associated cytomegalovirus colitis as a mimic of inflammatory bowel disease. Gut. 1995;37:148–50.

    Article  Google Scholar 

  58. Nelson MR, Shanson DC, Hawkins DA et al. Salmonella, Campylobacter and Shigella in HlV-seropositive patients. AIDS. 1992;6:1495–8.

    Article  PubMed  CAS  Google Scholar 

  59. Aviles-Izquierdo JA, Suarez-Fernandez R, Lazaro-Ochaita P, Longo-Imedio MI. Metastatic Crohn’s disease mimicking genital pyoderma gangrenosum in an HIV patient. Acta DermVenereol. 2005;85:60–2.

    Article  Google Scholar 

  60. Frances C. Kaposi’s sarcoma after renal transplantation. Nephrol Dial Transplant. 1998;13:768–73.

    Article  Google Scholar 

  61. Trattner A, Hodak E, David M et al. The appearance of Kaposi’s sarcoma during corticosteroid therapy. Cancer. 1993;72:1779–83.

    Article  PubMed  CAS  Google Scholar 

  62. Wijveen AC, Person H, Bjork S et al. Disseminated Kaposi’s sarcoma — füll regression after withdrawal of immunosuppressive therapy: report of a case. Transplant Proc. 1987;?:3735–6.

    Google Scholar 

  63. Thompson GB, Pemberfon JH, Morris S et al. Kaposi’s sarcoma of the colon in a young HIV-negative man with chronic ulcerative colitis. Report of a case. Dis Colon Rectum. 1989;32:73–6.

    Article  PubMed  CAS  Google Scholar 

  64. Tedesco M, Benevolo M, Frezza F et al. Colorectal Kaposi’s sarcoma in an HIV-negative male in association with ulcerative rectocolitis: a case report. Anticancer Res. 1999;19:3045–8.

    PubMed  CAS  Google Scholar 

  65. Bursics A, Morway K, Abraham K et al. HHV-8 positive, HIV negative disseminated Kaposi’s sarcoma complicating steroid dependent ulcerative colitis: a successfully treated case. Gut. 2005;54:1049–50.

    Article  PubMed  CAS  Google Scholar 

  66. Walker RE, Spooner KM, Kelly G et al. Inhibition of immunoreactive tumour necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis. 1996;174:63–8.

    PubMed  CAS  Google Scholar 

  67. Sha BE, Valdez H, Gelman RS et al. Effect of etarnecept on interleukin-6, tumour necrosis factor alpha and markers of immune activation in HIV infected subjeets reeeiving interleukin 2. AIDS Res Hum Retroviruses. 2002;18:661–5.

    Article  PubMed  CAS  Google Scholar 

  68. Wallis RS, Kyambadde P, Johnson JL et al. A study of safety, immunology, virology and microbiology of adjunctive etarnecept in HIV-1 associated tuberculosis. AIDS. 2004;18:257–64.

    Article  PubMed  CAS  Google Scholar 

  69. Beitran B, Nos P, Bastida B, Iborra M, Hoyos M, Ponce J. Safe and effective application of anti-TNFa in a patient infected with HIV and concomitant Crohn’s disease. Gut. 2006;54:1670–1.

    Article  Google Scholar 

  70. Torre-Cisneros J, del Castillo M, Caston JJ, Castro MC, Perez V, Collantes E. Infliximab does not activate replication of lymphotropic herpes viruses in patients with refractory rheumatoid arthritis. Rheumatology. 2005;44:1132–5.

    Article  PubMed  CAS  Google Scholar 

  71. Jacobson JM, Spritzler J, Fox L et al., for the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Thalidomide for the treatment of aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis. 1999;180:61–7.

    Article  PubMed  CAS  Google Scholar 

  72. Kaplan G, Thomas S, Fieter DS et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses. 2000;16:1435–55.

    Article  Google Scholar 

  73. Reyes-Teran G, Sierra-Madevo JG, Martinez del Cerro V et al. Effects of thalidomide on HlV-associated wasting syndrome: a randomized double-blind, placebo controlled clinical trial. AIDS. 1996;10:1501–7.

    PubMed  CAS  Google Scholar 

  74. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor a and interleukin 12 production in patients with active chronic Crohn’s disease. Gut. 2002;50:196–200.

    Article  PubMed  CAS  Google Scholar 

  75. Ehrenpreis ED, Kane SV, Cohen LB et al. Thalidomide therapy for patients with refractory Crohn’s disease: an open label trial. Gastroenterology. 1999;117:1271–7.

    Article  PubMed  CAS  Google Scholar 

  76. Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot study of low-dose thalidomide in chronically active steroid-dependent Crohn’s disease. Gastroenterology. 1999;117:1278–87.

    Article  PubMed  CAS  Google Scholar 

  77. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther. 2003;25:342–93.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, University Hospital, PO Box 1352, 71100, Heraklion, Crete, Greece

    E. A. Kouroumalis

Authors
  1. E. A. Kouroumalis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Marmara University, Istanbul, Turkey

    N. Tözün

  2. Yüksek İhtisas Hospital, Ankara, Turkey

    Ü. Dağlı

  3. Evangelismos Hospital, Athens, Greece

    G. Mantzaris

  4. Universität Regensburg, Regensburg, Germany

    J. Schölmerich

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer and Falk Foundation e.V.

About this chapter

Cite this chapter

Kouroumalis, E.A. (2008). Inflammatory bowel disease coexistent with viral hepatitis and HIV. In: Tözün, N., Dağlı, Ü., Mantzaris, G., Schölmerich, J. (eds) IBD 2007 — Achievements in Research and Clinical Practice. Falk Symposium, vol 159. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6987-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4020-6987-1_7

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-6986-4

  • Online ISBN: 978-1-4020-6987-1

  • eBook Packages: Medicine (R0)

Publish with us

Policies and ethics

Search

Navigation